Subject demographics, SCD characteristics, and descriptors of pVOC characteristics in stage 3
| . | Cohort (n = 27) . | Cohort by stage . | ||
|---|---|---|---|---|
| Stage 1 (n = 15) . | Stage 2 (n = 6) . | Stage 3 (n = 6) . | ||
| Demographics | ||||
| Age at infusion (y), median (IQR) | 33.5 (12) | 32.2 (11) | 35.8 (11) | 33.3 (11) |
| Gender, % male | 56 | 53 | 67 | 50 |
| SCD characteristics | ||||
| Hemogloblin (g/dL), median (IQR) | 7.6 (2) | 7.7 (2) | 7.5 (1) | 6.1 (2) |
| WBC (k/μL), median (IQR) | 8.4 (4) | 8.1 (2) | 11.6 (5) | 9.8 (3) |
| Hydroxyurea, % | 59 | 40 | 83 | 83 |
| pVOC admission characteristics | ||||
| Drug start time (d), median (IQR)* | NA | NA | NA | 3.5 (2) |
| Duration of stay (d), median (IQR) | NA | NA | NA | 6 (2) |
| Postdrug admittance in 4 wk, median (range) | 0 (0-2) | 0 (0) | 0 (0-2) | 0 (0-2) |
| . | Cohort (n = 27) . | Cohort by stage . | ||
|---|---|---|---|---|
| Stage 1 (n = 15) . | Stage 2 (n = 6) . | Stage 3 (n = 6) . | ||
| Demographics | ||||
| Age at infusion (y), median (IQR) | 33.5 (12) | 32.2 (11) | 35.8 (11) | 33.3 (11) |
| Gender, % male | 56 | 53 | 67 | 50 |
| SCD characteristics | ||||
| Hemogloblin (g/dL), median (IQR) | 7.6 (2) | 7.7 (2) | 7.5 (1) | 6.1 (2) |
| WBC (k/μL), median (IQR) | 8.4 (4) | 8.1 (2) | 11.6 (5) | 9.8 (3) |
| Hydroxyurea, % | 59 | 40 | 83 | 83 |
| pVOC admission characteristics | ||||
| Drug start time (d), median (IQR)* | NA | NA | NA | 3.5 (2) |
| Duration of stay (d), median (IQR) | NA | NA | NA | 6 (2) |
| Postdrug admittance in 4 wk, median (range) | 0 (0-2) | 0 (0) | 0 (0-2) | 0 (0-2) |
Stage 1, 12-hour infusion at steady state, dose-seeking; stage 2, 24-hour infusion at steady state, target dose (1.44 μg/kg/h); stage 3, 24-hour infusion during pVOC, target dose (1.44 μg/kg/h). IQR, interquartile range; NA, not applicable.
Days since hospital admission (time starts on admittance order).